Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHN Achillion Pharmaceuticals	$6.76	$6.76	$2.06 ▼ $7.01	$946.72M	1.59	8.44 million shs	N/A
BCRX BioCryst Pharmaceuticals	$8.59 -0.2%	$9.92	$6.02 ▼ $11.31	$1.80B	1.04	3.03 million shs	512,521 shs
FOLD Amicus Therapeutics	$6.06 +1.6%	$6.07	$5.51 ▼ $12.65	$1.87B	0.51	3.24 million shs	398,796 shs
LGND Ligand Pharmaceuticals	$141.62 +1.8%	$112.10	$90.29 ▼ $141.62	$2.71B	0.84	119,296 shs	34,609 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHN Achillion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+754.41%
BCRX BioCryst Pharmaceuticals	0.00%	-1.71%	-14.75%	+14.34%	+20.59%
FOLD Amicus Therapeutics	0.00%	-2.13%	+5.67%	-11.18%	-42.58%
LGND Ligand Pharmaceuticals	0.00%	+14.30%	+21.94%	+32.72%	+39.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	4.5294 of 5 stars	4.5	1.0	0.0	4.2	3.9	1.7	0.6
FOLD Amicus Therapeutics	4.1617 of 5 stars	3.4	1.0	0.0	4.3	3.4	0.0	1.9
LGND Ligand Pharmaceuticals	3.6589 of 5 stars	1.5	1.0	0.0	4.4	2.8	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHN Achillion Pharmaceuticals	0.00	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	94.34% Upside
FOLD Amicus Therapeutics	2.80	Moderate Buy	$16.22	167.91% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	3.92% Upside

Current Analyst Ratings Breakdown

Latest ACHN, LGND, FOLD, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	FOLD Amicus Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
BCRX BioCryst Pharmaceuticals	$450.71M	3.99	N/A	N/A	($2.30) per share	-3.74
FOLD Amicus Therapeutics	$543.14M	3.43	N/A	N/A	$0.65 per share	9.32
LGND Ligand Pharmaceuticals	$181.49M	15.06	$1.64 per share	86.57	$43.95 per share	3.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHN Achillion Pharmaceuticals	-$70.27M	-$0.51	N/A	N/A	N/A	N/A	-30.95%	-29.09%	N/A
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	1.41	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	14.08	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	38.17	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest ACHN, LGND, FOLD, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FOLD Amicus Therapeutics	$0.01	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.02	N/A	N/A	N/A	$149.59 million	N/A
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHN Achillion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHN Achillion Pharmaceuticals	0.01	8.96	8.96
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
FOLD Amicus Therapeutics	2.02	3.34	2.47
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHN Achillion Pharmaceuticals	79.42%
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ACHN Achillion Pharmaceuticals	4.58%
BCRX BioCryst Pharmaceuticals	4.80%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHN Achillion Pharmaceuticals	56	140.05 million	N/A	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

ACHN, LGND, FOLD, and BCRX Headlines

Recent News About These Companies

Bank of New York Mellon Corp Sells 3,421 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 21 at 3:26 AM | marketbeat.com

New York State Common Retirement Fund Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 19 at 4:22 AM | marketbeat.com

Jackson Creek Investment Advisors LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 18 at 10:26 AM | marketbeat.com

Stocks Showing Rising Market Leadership: Ligand Pharmaceuticals Earns 84 RS Rating

July 18 at 9:24 AM | msn.com

Ligand Pharmaceuticals Stock Earns 84 RS Rating

July 17, 2025 | msn.com

J&J boosts full-year outlook on forex tailwinds and operational performance

July 16, 2025 | msn.com

Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High - Still a Buy?

July 16, 2025 | marketbeat.com

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating

July 15, 2025 | msn.com

CenterBook Partners LP Purchases 44,760 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 15, 2025 | marketbeat.com

Rice Hall James & Associates LLC Sells 7,704 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14, 2025 | marketbeat.com

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14, 2025 | marketbeat.com

Stephens Investment Management Group LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 13, 2025 | marketbeat.com

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq

July 12, 2025 | nasdaq.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 Shares

July 12, 2025 | insidertrades.com

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

July 11, 2025 | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

July 11, 2025 | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11, 2025 | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10, 2025 | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10, 2025 | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9, 2025 | marketbeat.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 High-Risk, High-Reward Stocks With Explosive Upside
By Nathan Reiff | July 16, 2025
View 3 High-Risk, High-Reward Stocks With Explosive Upside

ACHN, LGND, FOLD, and BCRX Company Descriptions

Achillion Pharmaceuticals NASDAQ:ACHN

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.59 -0.02 (-0.20%)

As of 10:41 AM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$6.06 +0.10 (+1.59%)

As of 10:41 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$141.62 +2.52 (+1.81%)

As of 10:41 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time